Skip to main content

What is the difference between Renflexis and Remicade?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on March 26, 2025.

Official Answer by Drugs.com

Renflexis (infliximab-abda) is a tumor necrosis factor (TNF) blocker that is biosimilar to Remicade (infliximab).

According to the FDA, a biosimilar is shown to have no clinically meaningful differences in terms of safety and effectiveness from the reference product -- in this case Remicade. Only minor differences in clinically inactive components are allowable in biosimilar products.

Learn more: What Are Biosimilars? Top Facts You May Not Know

Renflexis is given as an intravenous (IV) infusion similar to Remicade, and is used for the same conditions, specifically treatment of:

The first biosimilar to Remicade, Pfizer’s Inflectra (infliximab-dyyb) was approved by the FDA in April, 2016.

For more information, see Comparing Remicade vs Renflexis.

Related questions

Which is more affordable, Renflexis or Remicade?

Dosing is based on your weight and clinical condition. See more information here:

This is not all the information you need to know about Remicade or Renflexis for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full product information, and discuss this information and any questions you have with your doctor or other health care provider.

References

Read next

What is the difference between Inflectra and Remicade?

Inflectra (infliximab-dyyb) is a biosimilar to Remicade (infliximab). They belong to the same class of drugs called tumor necrosis factor (TNF) alfa inhibitors. Inflectra can be prescribed for the same uses as Remicade, including rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, and plaque psoriasis. Continue reading

Biosimilars vs Biologics: What are they and how do they compare?

A biosimilar is a biological product that is similar to a reference biologic (usually the originally approved product) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. The most recent biosimilar approval was Kristy (insulin aspart-xjhz), a rapid acting human insulin analog interchangeable biosimilar to NovoLog (insulin aspart), on July 15, 2025.

Continue reading

What are Monoclonal Antibodies and how do they work?

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis.

Continue reading

See also:

Related medical questions

Drug information

Related support groups